Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The Agricultural Revolution was almost certainly associated with a substantial decrease in human calcium intake. Calcium intakes typical of contemporary humans may well be inadequate for many individuals. Various slowly developing chronic disorders such as osteoporosis, hypertension, hyperlipidemia, and colon cancer may be induced or exaggerated by the current low level of dietary calcium intake in Western societies. We propose two hypotheses relating calcium intake to diverse diseases: first, the adaptation required to adjust to low intakes is inadequate to maintain critical components of cellular calcium regulation; second, the constant, forced adaptive response to low intake itself produces untoward consequences.
...
PMID:Dietary calcium and chronic diseases. 219 36

Dietary fiber has been, for several years, the glamour ingredient in popular nutrition. Based on epidemiological evidence, lack of fiber in the diet has been impugned as a major risk factor for development of colon cancer, heart disease, diabetes and a variety of lesser ills. Animal experiments suggest that some components of the complex mixture of substances called fiber will reduce cholesterol levels to a modest extent and will inhibit atherosclerosis induced by diet. In man the data center on the effects of fiber on plasma cholesterol levels and some fibers such as pectin or guar exert significant hypocholesterolemic effects whereas others, such as bran, do not. The situation is similar with regard to colon cancer. Some types of fiber, bran and cellulose for instance, inhibit experimentally induced colon cancer. There are a number of ways of establishing experimental colon cancer; feeding the carcinogenic agent, injecting it, or instilling it intrarectally. There also exists a variety of carcinogenic agents. The effect of fiber is the sum of the type of fiber and carcinogen used and the mode of establishing the cancer. Different combinations give different results in animal studies. In man the data bearing on this subject are wholly epidemiological. A few case-control studies have provided suggestions that low fiber diets may predispose to colon cancer but these studies point to a dietary life-style in which many components other than fiber vary. The most notable success in wedding practice to hypothesis has been in the area of diabetes. Here it has been shown clearly that increasing dietary fiber results in reductions in lipemia, glycemia and insulin requirement. What remains? More work in the cancer and heart disease fields but mainly a greater effort to identify the specific structure of those fibers which exert a beneficial effect. This will have the two-fold benefit of identification of specifically useful structural types of fiber and of possibly providing clues to mechanism of action or of carcinogenicity. Most experts agree that a modest increase in intake of fiber will have a generally beneficial effect but they can only support these statements with epidemiological proof. Future research must include studies designed to confirm the epidemiological findings and to identify the specific components responsible for them.
...
PMID:The role of dietary fiber in health and disease. 301 64

A project on "Aggregation of Red Cells" has been accepted by NASA in 1977. An automated slit-capillary photo-viscometer has been designed during 1979-1984, and its last version met NASA's space hazards requirements. The 'heart' of instrument is a set of two highly polished glass plates, spaced by a gap of 12.5 micrometers. An original drum-like infusion pump allows utilization of up to eight blood samples. During a sequential process, blood flows through the slit, and then stops to allow formation of aggregates. Micro- and macro-photography is carried out, and 500 photographs are obtained. Blood from normal donors and patients with history of ischaemic heart disease, colon cancer, juvenile-onset diabetes, hyperlipidaemia, etc., is anticoagulated and adjusted to haematocrit of 0.30 using native plasma. Samples are divided, and infused into the 'flight' and 'ground' instruments. Prior to experiment temp. is 5 degrees C; temp. during experiment is 25 degrees C. Experiments took place on 24-25 January 1985, on the middeck of space shuttle 'Discovery'. Subsequent results showed that red blood cells do not change shape under zero gravity; that aggregation of red cells does take place; that aggregates in pathologic blood show morphology of normal rouleaux under zero gravity, while identical blood shows clumps of red cells on the ground. The latter observation suggests that zero gravity might affect cell-to-cell interaction, and perhaps microstructure of the cell membrane. These aspects must remain however tentative till a confirmation by subsequent experiments can be obtained.
...
PMID:Execution of "ARC" experiment on space shuttle "Discovery" STS 51-C: some results on aggregation of red blood cells under zero gravity. 377 59

The concept of predictive medicine based on the detection of genetic markers for disease susceptibility stemmed from the finding that many diseases are associated with specific HLA alleles. This model suggested that similar associations probably existed with other genes located all along the human genome. The Human Specimen Study Center (HSSC) was created to assist in investigating this possibility and has contributed significantly to the knowledge contained in current genetic and physical human genome maps. Predictive medicine is intended not for patients but for healthy individuals, its goal being to determine whether their susceptibility to a specific disease is increased or not. Fetuses with evidence of disease are excluded from the province of predictive medicine, which can, however, determine whether a healthy fetus is at high risk for developing a disease in adolescence or adulthood. Predictive medicine is based on probabilities: it evaluates diseases susceptibility but cannot predict with 100% certainty that a specific disease will occur. Whereas many preventive interventions are directed at groups (e.g., immunization programs), predictive medicine is conducted on an individualized basis. For instance, glaucoma is a monogenic disease whose early detection can allow to prevent permanent loss of vision. The fruits of predictive medicine are expected to be greatest, however, in the polygenic multifactorial diseases that are prevalent in industrialized countries, such as diabetes mellitus, hypertension, myocardial infarction, hyperlipidemia, and arteriosclerosis. An ability to detect subjects who are susceptible to breast cancer would be extraordinarily useful, and may be a goal within reach since two breast cancer susceptibility genes have already been identified. Genes associated with increased susceptibility to colon cancer have also been reported. Predictive medicine raises a number of sensitive ethical issues. Individuals should be free to accept or decline disease susceptibility testing after having been fully informed. Confidentiality is vital. The results of susceptibility tests should not be made available to employers or insurance agencies. Susceptibility testing should be offered only if the disease requires a specific treatment or lifestyle modification. Unnecessary anxiety may be one of the main adverse effects of susceptibility testing. A large number of disease susceptibility or resistance genes will probably be identified in the near future, and this will inevitably have an impact on the way physicians approach their patients. Physicians in the XXIst century will spend an increasingly large proportion of their time counselling their patients on how to stay healthy. This trend can be expected to translate into a marked increase in life expectancy. Rather than seeking to add years to life, physicians will strive to add life to years.
...
PMID:[Predictive medicine and its ethics]. 929 63

Epidemiological studies have shown a positive association of colon cancer with hyperlipidemia. Furthermore, signaling generated by peroxisome proliferator-activated receptor (PPAR) alpha and gamma ligands, suggested to be candidate tumor preventive agents, has been shown to lower serum triglyceride levels. In the present study, we assessed hyperlipidemia in Apc-deficient mice, model animals for human familial adenomatous polyposis, and examined the effects of pioglitazone and bezafibrate, respectively, PPARgamma and PPARalpha agonists, on both hyperlipidemia and intestinal polyposis. Serum lipid levels in Apc(1309) mice and Min mice from 6 to 15 weeks of age were measured. Although serum levels of triglyceride and cholesterol were low in both Apc(1309) and wild-type mice at 6 weeks, triglycerides were elevated 10-fold in Apc(1309) mice by the age of 12 weeks but not in their wild-type counterparts. Cholesterol was also increased significantly, and marked centrilobular-restricted steatosis was observed in the livers of aged Apc(1309) mice. Similar findings were observed for Min mice at 15 weeks of age. Moreover, lipoprotein lipase mRNA levels in the liver and small intestine of Apc(1309) and Min mice were demonstrated to be lower than those in wild-type mice. Treatment of Apc(1309) mice with 100 and 200 ppm pioglitazone or bezafibrate for 6 weeks from 6 weeks of age caused dose-dependent reduction in serum triglycerides and cholesterol, along with reduction in the numbers of intestinal polyps to 67% of the control value. The present study clearly demonstrated a hyperlipidemic state in Apc gene-deficient mice and a potential of PPARalpha and PPARgamma ligands to suppress both hyperlipidemia and polyp formation. Hyperlipidemia in these mice may thus be associated with their intestinal lesion development.
...
PMID:Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. 1452 40

In our previous study, a peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist, pioglitazone, suppressed both hyperlipidemia and intestinal polyp formation in Apc(1309) mice at doses of 100 and 200 ppm in the diet. In contrast, it has been reported that doses of 1500 or 2000 ppm of another PPAR gamma agonist, troglitazone, enhanced colon polyp development in Min mice. In the present study, we therefore investigated the effects of a wide range of pioglitazone doses on both hyperlipidemia and intestinal polyp formation in Min mice. Serum triglycerides and very low density lipoprotein (VLDL) cholesterol in the basal diet group were elevated to levels 13-15 times higher than those in the wild-type counterparts at 20 weeks of age. They were reduced dose-dependently by treatment with 100, 200, 400 and 1600 ppm pioglitazone from 6-20 weeks of age with suppression to almost the wild-type level at the highest dose. Moreover, up-regulation of the liver mRNA levels for lipoprotein lipase (LPL) was evident in the pioglitazone-treated animals. Dose-dependent reduction of intestinal polyps was observed in Min mice given 100-1600 ppm for 14 weeks, total numbers being decreased to 63-9% of the control value. A suppressive effect of pioglitazone on colon polyp formation was also found. The PPAR gamma agonist, pioglitazone, may thus be a promising candidate chemopreventive agent for colon cancer.
...
PMID:Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. 1461 72

In a matched case-control study using the General Practice Research Database, current statin use was not associated with a significantly altered risk of any of 13 studied cancers. Untreated hyperlipidaemia was associated with slightly increased risks of colon cancer (relative risk 1.8; 95% confidence interval 1.2-2.8), prostate cancer (1.5; 1.1-2.0), and bladder cancer (1.9; 1.2-3.1).
...
PMID:Statin use and cancer risk in the General Practice Research Database. 1476 Mar 77

We have previously reported a hyperlipidemic state in two strains of Apc-deficient mice, Min and Apc(1309), associated with low expression levels of lipoprotein lipase (LPL) in the liver and small intestine, and enforced induction of LPL mRNA by peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma agonists clearly suppressed hyperlipidemia and intestinal polyp formation in these mice. Meanwhile, a compound, NO-1886, has been shown to increase LPL mRNA and protein levels but not to possess PPARalpha and PPARgamma agonistic activity. In this study, therefore, the effects of NO-1886 on hyperlipidemia and intestinal polyp formation were investigated in Min mice. Administration of 400 and 800 ppm NO-1886 in the diet for 13 weeks from 7 weeks of age caused a reduction of serum triglycerides to 39% and 31% of the untreated value, respectively, and the values for very low-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were improved almost to the wild-type level with a corresponding elevation of the LPL mRNA. Moreover, total numbers of intestinal polyps in the groups receiving NO-1886 at 400 and 800 ppm were decreased to 48% and 42% of the control value, respectively. We also found that NO-1886 suppressed cyclooxygenase-2 transcriptional promoter activity in a reporter gene assay and reduced cyclooxygenase-2 mRNA levels in the small intestine of Min mice. These results indicate that suppression of serum lipid levels by increasing LPL activity may contribute to a reduction of intestinal polyp formation with Apc-deficiency, and NO-1886 and its derivatives could be useful as chemopreventive agents for colon cancer.
...
PMID:Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. 1571 Aug 87

Acquired hemophilia A (AHA) is a rare coagulation disorder due to the development of an autoantibody against and inhibitor of coagulation factor VIII. It has been reported that immunosuppressive therapy with corticosteroids, cyclophosphamide, azathioprine and vincristine are effective to decrease this inhibitor. When corticosteroids and cytotoxic drugs are ineffective, cyclosporine A (CyA) may be effective as a second-line salvage therapy. Except for postpartum conditions, AHA usually occurs in elderly patients who are often already suffering from diabetes mellitus, ischemic heart disease and/or hyperlipidemia. However, immunosuppressive and cytotoxic drugs may have adverse effects on these patients. We report on a 66-year-old man who developed AHA after colon cancer resection (factor VIII inhibitor: 61 Bethesda units/ml, aPTT : 97.9 s). Since he already had both diabetes mellitus and ischemic heart disease, we abandoned treatment with corticosteroids and oral cyclophosphamide was started, but was switched to CyA because of leukopenia. Within 3 months of starting the CyA treatment, aPTT levels returned to normal and 4 further months were required for complete eradication of the inhibitor. This case revealed that CyA is as effective as corticosteroids for AHA. For patients with AHA who have unfavorable complications due to corticosteroids and cytotoxic drugs, CyA could be a potential first-line drug.
...
PMID:[Cyclosporine A as an effective treatment for a patient with acquired hemophilia A complicated with diabetes mellitus and ischemic heart disease]. 1644 Jul 70

Epidemiologically, a high-fat diet is associated with the risk of colon cancer. In addition, serum levels of triglycerides (TGs) and cholesterol have been demonstrated to be positively associated with colon carcinogenesis. We recently found that an age-dependent hyperlipidemic state (high serum TG levels) exists in Apc-deficient mice, an animal model for human familial adenomatous polyposis. The mRNA levels of lipoprotein lipase (LPL), which catalyzes TG hydrolysis, were shown to be downregulated in the liver and intestines of mice. Moreover, treatment with a peroxisome proliferator-activated receptor (PPAR) alpha agonist, bezafibrate, or a PPARgamma agonist, pioglitazone, suppressed both hyperlipidemia and intestinal polyp formation in the mice, with induction of LPL mRNA. PPARalpha and PPARgamma agonists are reported to exert anti-proliferative and pro-apoptotic effects in cancer cells. One compound that also increases LPL expression levels but does not possess PPAR agnostic activity is NO-1886. When given at 400 or 800 ppm in the diet, it suppresses both hyperlipidemia and intestinal polyp formation in Apc-deficient mice, with elevation of LPL mRNA. In conclusion, a decrease in serum lipid levels by increasing LPL activity may contribute to a reduction in intestinal polyp formation with Apc deficiency. PPARalpha and PPARgamma agonists, as well as NO-1886, could be useful as chemopreventive agents for colon cancer.
...
PMID:Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. 1660 35


1 2 3 Next >>